Gilead Didn't Pay Teva In HIV Drug IP Deal, Economist Says

By Bonnie Eslinger (June 26, 2023, 9:52 PM EDT) -- An economics expert for Gilead and Teva, testifying Monday in a federal antitrust trial over claims the pharmaceutical giants struck an illegal "pay for delay" patent deal over two HIV medications, said a settlement provision allowing Teva to enter the market six months ahead of other generics had no value....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!